Welcome to Biomed Industries, Inc. ™



  • Biomed Industries™, Inc's goal is to mitigate human suffering.
    Biomed is committed to the development and commercialization of new drug therapeutics for unmet needs in neurodegenerative diseases, metabolic disorders, and cardiovascular diseases and rare diseases:

    NA-704:     for Amyotrophic Lateral Sclerosis (ALS) (Phase 2B)
    NA-731: for Traumatic Brain Injury (Phase 2A)
    NA-831: for Mild and Moderate Alzheimer’s Disease (Phase 2B/3)
    NA-901: for Major Depressive Disorder (Phase 2B/3)
    NA-911: for Stroke (Phase 2A)
    NA-921: for Rett Syndrome and Fragile X (Phase 2B/3)
    NA-931: for Diabetes Obesity (Phase 2B/3)
    NA-941: for Metabolic dysfunction-associated steatohepatitis (MASH) (Phase 2A)
    MICROS: MICROS Infusion System (Approved for marketing by the FDA)
    • Learn more


    Latest Press Release

    Press Release
    Biomed Industries, Inc. presented Phase 1 results of NA-931, an Oral Novel Quadruple Receptor Agonist for Weight Loss at the World Obesity & Weight Management Congress 2024
    November 4, 2024
    Click here to view press release

    Biomed Industries, Inc. Announces Positive Phase I Results of Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment
    October 7, 2024
    Click here to view press release

    Biomed Industries Unveils Novel Quadruple Receptor Agonist for Remarkable Weight Loss with Minimal Adverse Effects at the 2024 International Obesity Conference
    September 23, 2024
    Click here to view press release

    Biomed Industries Unveils a New Neurogenesis Hypothesis with Clinical Data for Alzheimer's and Depression Treatment
    September 9, 2024
    Click here to view press release

    More News

    A New Treatment for Alzheimer's Disease

    New treatment for AD



  • NA-831, designed to treat Alzheimer’s disease, is an oral medication with a clean safety profile administered at 30 mg daily.
    This groundbreaking drug, developed in-house by the Biomed research team, has been successful in Phase 2A clinical trials, and the company is preparing for Phase 3.
    The drug exhibits neuroprotective properties, and most notably facilitates the brain's ability to generate new neurons (neurogenesis), enhancing memory and cognitive functions in patients with Alzheimer's disease.

    • Learn more
    NA-931 for treating Diabetes Obesity

    Obese and scale


    Obesity is associated with the impairment of normal GH (growth hormone), GLP-1 secretion, and responses to all stimuli such as GH-releasing hormone (GHRH), hypoglycaemia, L-dopa, arginine, glucagon, physical exercise, and sleep.
    Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion.
    NA-931™ regulates the homeostasis of insulin-like growth factor (IGF-1) function and GLP-1 associated with diabetes obesity.

    Learn more
    NA-911™ for the treatment of STROKE

    stroke patient


    On average, every 40 seconds, someone in the United States has a stroke. Stroke is the No. 5 cause of death a leading cause of serious long-term disability. The current treatment for stroke is using tissue plasminogen activator (tPA) to breaks up the blood clots that block blood flow to the brain. NA-911 is a breakthrough for the treatment and prevention of stroke.
    NA-911™ is a neuroprotective drug, designed to protect the brain from the damages caused by stroke, or other hypoxic or ischemic injury of the brain.


    Learn more
    NA-941 for treating MASH

    MASH liver


    Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis or NASH) is a type of fatty liver disease. It often develops due to a metabolic disorder, such as obesity or diabetes, resulting in a toxic buildup of fat in the liver.
    NA-941™ regulates the homeostasis of insulin-like growth factor (IGF-1) function associated with fatty liver disease.


    Learn more
    Biomed AI

    Biomed AI


    Biomed is actively gathering and consolidating extensive datasets, utilizing advanced machine learning techniques to expedite the process of drug discovery and development.
    Through the integration of high-content data using artificial intelligence, Biomed delves deeply into the mechanisms of action of diverse drug therapeutics. This approach enables us to swiftly pinpoint safe and efficacious therapies, ultimately benefiting patients.
    Our platform furnishes a robust pipeline of top-tier therapeutic interventions, supporting both our internal initiatives and collaborative drug discovery endeavors.

    Learn more
    Traneurocin NA-831 bottle
    NA-831™ for the treatment of mild & moderate Alzheimer’s Disease

    NA-831 provides neuroprotection and catalyzes the regeneration of new neurons. Phase 2A clinical trials of NA-831 showed a proof of safety and efficacy for mild and moderate Alzheimer’s Disease.

    Learn more
    depression
    NA-901™ for Major Depressive Disorder (MDD)

    NA-901 shows promise as a treatment for Major Depressive Disorder. Results of a Phase 1B study have demonstrated a excellent safety profile with no adverse side effects. NA-901 is ready for Phase 2/3 for the treatment of MDD.

    Learn more
    obesity
    NA-931™ for the treatment of Diabetes Obesity

    NA-931 regulates the homeostasis of insulin-like growth factor (IGF-1) function and GLP-1 associated with diabetes obesity. NA-931 is a small molecule drug, available in an oral formulation. It can significantly reduce the body mass index, without causing muscle loss.

    Learn more
    ALS patient
    NA-704™ for the treatment of Amyotrophic Lateral Sclerosis (ALS)

    NA-704 stimulates neurogenesis and reduce muscular spasticity, a candidate for ALS and Parkinson’s disease. NA-704 exhibits neuroprotection and it has great bioavailability in the body. NA-704 is in the Phase 2A clinical trials.

    Learn more
    Rett-Syndrome-girl
    NA-921™ for the treatment of Rett-Syndrome

    NA-921™is a small molecule drug that is in Phase 2/3 clinical trials for the treatment of Rett Syndrome. NA-921 can easily crosses the blood brain barrier, so only a small dose of the drug is required to be effective.

    Learn more
    MICROS
    MICROS™ infusion system

    The MICROS is a controlled release infusion system which has been approved for marketing in the US. It is used for intravenous administration of injectable drugs. NA-704 can be administered via the MICROS at home care settings. It is an accurate, safe and cost effective drug delivery system.

    Learn more
    Neurogenesis
    Neurogenesis and
    Alzheimer's Disease

    NA-831 restores neurogenesis by increasing the expression of BDNF (brain derived neurotrophic factor). NA-831 serves as a catalyst to restore neurogenesis in Alzheimer’s patients, with higher numbers of neuroblasts leading to improved cognitive function. Learn more
    Neuroprotection and Major Depressive Disorder

    NA-831, with its neuroprotective properties, may offer therapeutic potential for Major Depressive Disorder (MDD) by safeguarding neuronal health, enhancing synaptic connectivity, and potentially counteracting the neurodegenerative aspects of the illness.
    Learn more
    Depression